Compare CWBC & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWBC | MRVI |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | United States | United States |
| Employees | 341 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 648.6M | 472.8M |
| IPO Year | N/A | 2020 |
| Metric | CWBC | MRVI |
|---|---|---|
| Price | $24.20 | $3.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $28.00 | $4.13 |
| AVG Volume (30 Days) | 154.2K | ★ 1.9M |
| Earning Date | 04-17-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $39.58 | $12.44 |
| Revenue Next Year | $17.64 | $7.90 |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.87 | $1.67 |
| 52 Week High | $25.72 | $4.11 |
| Indicator | CWBC | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 66.10 | 57.59 |
| Support Level | $22.02 | $3.25 |
| Resistance Level | $24.77 | $3.93 |
| Average True Range (ATR) | 0.41 | 0.16 |
| MACD | 0.18 | 0.04 |
| Stochastic Oscillator | 93.75 | 86.11 |
Community West Bancshares is a bank holding company whose principal business is to serve as the holding company for its wholly-owned subsidiary Community West Bank N.A. Through CWB, the company provides a variety of financial products and full-service Banking Centers within California's Greater Sacramento, San Joaquin Valley, and Central Coast regions, that provide Commercial Lending, Real Estate, Agribusiness, Private Banking, and Cash Management Departments. The company has one reportable segment: Banking operations. Loans and leases, investment securities, interest-bearing deposits and non-interest income provide the revenues of the banking operation.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.